Be careful, though - the company's mergers and partnerships come with risk.
The focus was on new drugs under development and bringing them to market.
Goldman upgrades the early recovery plays; also, gauging Chinese growth and the swine flu effect on pork producers.
Expect a lively Q&A as management finesses the robust pipeline prospects in the face of coming generic exposure.
The stock's impressive rebound makes investors look well into the next decade to justify further gains.